Celsion Corporation (CLSN) Stock Price Increases Today

December 7, 2017 - By Henry Gaston

The stock of Celsion Corporation (NASDAQ:CLSN) is a huge mover today! The stock increased 7.11% or $0.17 during the last trading session, reaching $2.56. About 887,868 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 82.71% since December 7, 2016 and is downtrending. It has underperformed by 99.41% the S&P500.
The move comes after 5 months positive chart setup for the $41.12M company. It was reported on Dec, 7 by Barchart.com. We have $2.69 PT which if reached, will make NASDAQ:CLSN worth $2.06 million more.

Celsion Corporation (NASDAQ:CLSN) Ratings Coverage

Among 2 analysts covering Celsion (NASDAQ:CLSN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celsion had 9 analyst reports since August 7, 2015 according to SRatingsIntel. Maxim Group maintained the shares of CLSN in report on Monday, August 7 with “Hold” rating. Maxim Group maintained the shares of CLSN in report on Tuesday, August 15 with “Hold” rating. Maxim Group maintained it with “Buy” rating and $9.0 target in Tuesday, January 19 report. On Thursday, November 10 the stock rating was downgraded by Maxim Group to “Hold”. The firm earned “Hold” rating on Wednesday, August 12 by Zacks. The firm earned “Buy” rating on Thursday, October 5 by Maxim Group. As per Monday, November 20, the company rating was initiated by Oppenheimer. On Friday, August 7 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The company was maintained on Thursday, June 1 by Maxim Group.

More important recent Celsion Corporation (NASDAQ:CLSN) news were published by: Seekingalpha.com which released: “Celsion Turns Up The Heat On Cancer” on November 23, 2017, also Globenewswire.com published article titled: “CORRECTING and REPLACING — Celsion Files Immunotherapy Clinical Protocol for …”, Livetradingnews.com published: “Celsion Corporation (NASDAQ:CLSN) Advances 9.44%” on November 24, 2017. More interesting news about Celsion Corporation (NASDAQ:CLSN) was released by: Globenewswire.com and their article: “Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides …” with publication date: November 14, 2017.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $41.12 million. The companyÂ’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.